Adept Therapeutics

Adept Therapeutics is a pre-clinical stage biotechnology company focused on developing targeted therapies for solid tumors. The company's lead candidate, Adept-1, is a targeted peptide that specifically binds to Glucose-Regulated Protein 78 (GRP78), a protein overexpressed on the surface of various cancer cells, including ovarian, breast, and pancreatic cancers. By targeting GRP78, Adept-1 aims to deliver therapeutic payloads directly to tumor cells while minimizing off-target effects on healthy tissues. The company was founded as a spin-out from the University of South Florida to commercialize research into targeted cancer treatments. Adept Therapeutics is currently advancing its pipeline through pre-clinical studies to support future clinical development.